To the full analysis
LivaNova stock: growth
LIVNLivaNova reported $1.39B in revenue for fiscal 2025, up 10.7% on the prior year, up 8.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
13.6%
per year from 2006 to 2025, per share 9%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 8.2% | 16.9% | 13.6% |
| Revenue per share | 5.8% | 8.7% | 9.0% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | 9.0% | no data |
| Free cash flow per share | no data | 1.4% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $123.44M | −$59.07M | −$75.18M |
| 2007 | $130.97M | −$51.18M | −$22.11M |
| 2008 | $121.23M | −$10.33M | $13.64M |
| 2009 | $143.6M | $26.72M | $21.92M |
| 2010 | $167.78M | $78.45M | $36.76M |
| 2011 | $190.46M | $46.73M | $42.49M |
| 2012 | $218.5M | $36.08M | $57.04M |
| 2013 | $254.32M | $46.36M | $64.75M |
| 2014 | $282.01M | $54.89M | $35.13M |
| 2015 | $291.56M | $57.85M | $72.99M |
| 2016 | $1.21B | −$62.8M | $53M |
| 2017 | $1.01B | −$25.1M | $57.2M |
| 2018 | $1.11B | −$189.4M | $82.5M |
| 2019 | $1.08B | −$157.64M | −$115.83M |
| 2020 | $934.24M | −$348.82M | −$114.4M |
| 2021 | $1.04B | −$135.82M | $77.07M |
| 2022 | $1.02B | −$86.25M | $43.4M |
| 2023 | $1.15B | $17.55M | $39.93M |
| 2024 | $1.25B | $63.23M | $135.93M |
| 2025 | $1.39B | −$242.5M | $173.2M |
Revenue by segment
How LivaNova PLC makes its money and how that has shifted. Names are as the company reports them.
- Cardiopulmonary57%
- Neuromodulation43%
- Other< 1%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| Cardiopulmonary | $482.98M | $500.31M | $588.98M | $683.51M | $785.39M | 56.6% |
| Neuromodulation | $456.17M | $476.99M | $519.71M | $554.22M | $592.81M | 42.7% |
| Other | $96.21M | $44.5M | $44.86M | $15.7M | $0 | 0% |
| Total revenue | $1.04B | $1.02B | $1.15B | $1.25B | $1.39B | 100% |
Revenue by region
Where LivaNova PLC generates its revenue.
- United States53%
- Locations Excluding The United States And Europe27%
- Europe19%
Figures as a table
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|
| United States | $468.63M | $571.3M | $571.56M | $635.04M | $695.08M | $739.57M | 53.3% |
| Locations Excluding The United States And Europe | $272.24M | $262.54M | $271.45M | $303.71M | $338.32M | $379.3M | 27.3% |
| Europe | $193.37M | $201.53M | $178.8M | $214.79M | $220.03M | $269.18M | 19.4% |
| Total revenue | $934.24M | $1.04B | $1.02B | $1.15B | $1.25B | $1.39B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 14 Nov 2025)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.